---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053194"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:25:00.853054+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Omega Therapeutics Q1 net loss $20.1M; cash $60M funds into Q1 2025; OTX-2002 advances

## Summary
- Net loss of $20.1M for Q1 2024 vs $25.3M in Q1 2023; R&D expenses fell 23% to $15.4M.
- Cash and cash equivalents $60.0M as of March 31, 2024; expected to fund operations into Q1 2025.
- Phase 1/2 MYCHELANGELO I trial of OTX-2002 advanced to Cohort 5 at 0.3 mg/kg; additional data expected mid-2024.
- Presented preclinical data for MYC-targeting epigenomic controller in EGFRi-resistant NSCLC at AACR 2024.
- New preclinical data on durable gene upregulation to be presented at ASGCT 2024.

## SEC filing metadata
- accession: 0000950170-24-053194
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/0000950170-24-053194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/omga-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053194
- JSON: https://secwatch.observer/filing/0000950170-24-053194.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053194.txt

## Key facts
- Earnings Releases
  Omega Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $20.1 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $20.1 million
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $20.1 million, compared to $25.3 million for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/0000950170-24-053194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.